Physician profile
Jorge E Rodriguez
NPI 1801874375
$246,300.77
in general payments reported to CMS, 2019-2025
22 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $7,756 · 2021: $7,188 · 2022: $12K · 2023: $41K · 2024: $64K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Travel and Lodging: $21K · Consulting Fee: $10K · Food and Beverage: $5,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,317.50 |
| Travel and Lodging | $20,845.70 |
| Consulting Fee | $10,450.00 |
| Food and Beverage | $5,531.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $215,575.92 | 2019-2025 | Descovy, Biktarvy, Sunlenca |
| Viiv Healthcare Company | $28,228.24 | 2019-2024 | Apretude, Dovato, Cabenuva |
| Glaxosmithkline, LLC. | $1,138.85 | 2019 | |
| Emd Serono, INC. | $396.10 | 2024-2025 | |
| Boston Scientific Corporation | $323.77 | 2019-2025 | Watchman Flx |
| Antares Pharma, INC. | $131.44 | 2019-2021 | |
| Theratechnologies INC. | $114.64 | 2025 | Egrifta |
| Merck Sharp & Dohme LLC | $45.30 | 2025 | |
| Metuchen Pharmaceuticals | $45.25 | 2019-2020 | |
| Abiomed | $42.21 | 2025 | |
| Edwards Lifesciences Corporation | $41.35 | 2025 | |
| Neotract INC. | $36.01 | 2019 | |
| Novo Nordisk INC | $24.99 | 2023 | Wegovy |
| Abbvie INC. | $24.42 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $21.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.25 | 2021 | |
| Janssen Biotech, INC. | $18.28 | 2019 | |
| Endo Pharmaceuticals INC. | $16.91 | 2020 | |
| Sagent Pharmaceuticals | $16.90 | 2021 | |
| Mission Pharmacal Company | $13.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.